roche obesity - Search News

Roche, obesity and Zealand

Reuters on MSN · 2d

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

CNBC on MSN · 2d

Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Financial Times · 2d

Roche agrees biggest-ever obesity drug deal

Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma.

Fierce Biotech2d

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

3don MSN

Roche Hires Novo Executive to Help Push Into Obesity Drug Market

Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the ...

Medical Dialogues4h

Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results